Kanika Mehta , Dianna J. Magliano , Bendix Carstensen , Agus Salim , Jedidiah I. Morton , Julie Abimanyi-Ochom , Kaarin J. Anstey , Jonathan E. Shaw , Julian W. Sacre
{"title":"2003-2016 年间,2 型糖尿病及其持续时间对澳大利亚人口痴呆死亡发生率和药物处方的影响。","authors":"Kanika Mehta , Dianna J. Magliano , Bendix Carstensen , Agus Salim , Jedidiah I. Morton , Julie Abimanyi-Ochom , Kaarin J. Anstey , Jonathan E. Shaw , Julian W. Sacre","doi":"10.1016/j.diabres.2024.111795","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>To quantify rates of dementia treatment and death among Australians with type 2 diabetes relative to those without diabetes using linked national registries of Australia.</p></div><div><h3>Methods</h3><p>The study included 891,418 people with type 2 diabetes registered on the National Diabetes Services Scheme and a randomly sampled, population-based comparison group (n = 1,131,369). Outcomes included dementia death (all-cause dementia, Alzheimer’s disease (AD) or vascular dementia), and first prescription of cholinesterase inhibitors or memantine.</p></div><div><h3>Results</h3><p>Excess dementia risk was observed in the diabetes group for the composite outcome of all-cause dementia death or dementia medication prescription but varied with age at diabetes diagnosis and its duration. At age 70, the rate of dementia death/medication prescription was ∼1.3 (95% CI 1.2, 1.3) and 1.1 (95% CI 1.1, 1.2) times higher in people with ten and five years of diabetes duration, respectively. Individual outcomes showed that diabetes was associated with a higher incidence of vascular dementia death, whereas an increased risk of AD death was only observed beyond ∼10 years of diabetes duration. Further, the incidence of dementia medication prescription was lower among people with diabetes.</p></div><div><h3>Conclusions</h3><p>A higher incidence of AD death in the setting of 10+ years of diabetes duration coupled with a lower incidence of AD treatment suggests an under-recognition of this dementia phenotype among people with type 2 diabetes.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of type 2 diabetes and its duration on incidence rates of dementia death and medication prescription in the Australian population during 2003–2016\",\"authors\":\"Kanika Mehta , Dianna J. Magliano , Bendix Carstensen , Agus Salim , Jedidiah I. Morton , Julie Abimanyi-Ochom , Kaarin J. Anstey , Jonathan E. Shaw , Julian W. Sacre\",\"doi\":\"10.1016/j.diabres.2024.111795\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><p>To quantify rates of dementia treatment and death among Australians with type 2 diabetes relative to those without diabetes using linked national registries of Australia.</p></div><div><h3>Methods</h3><p>The study included 891,418 people with type 2 diabetes registered on the National Diabetes Services Scheme and a randomly sampled, population-based comparison group (n = 1,131,369). Outcomes included dementia death (all-cause dementia, Alzheimer’s disease (AD) or vascular dementia), and first prescription of cholinesterase inhibitors or memantine.</p></div><div><h3>Results</h3><p>Excess dementia risk was observed in the diabetes group for the composite outcome of all-cause dementia death or dementia medication prescription but varied with age at diabetes diagnosis and its duration. At age 70, the rate of dementia death/medication prescription was ∼1.3 (95% CI 1.2, 1.3) and 1.1 (95% CI 1.1, 1.2) times higher in people with ten and five years of diabetes duration, respectively. Individual outcomes showed that diabetes was associated with a higher incidence of vascular dementia death, whereas an increased risk of AD death was only observed beyond ∼10 years of diabetes duration. Further, the incidence of dementia medication prescription was lower among people with diabetes.</p></div><div><h3>Conclusions</h3><p>A higher incidence of AD death in the setting of 10+ years of diabetes duration coupled with a lower incidence of AD treatment suggests an under-recognition of this dementia phenotype among people with type 2 diabetes.</p></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168822724007058\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822724007058","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的:利用澳大利亚相关的国家登记资料,量化澳大利亚2型糖尿病患者与非糖尿病患者的痴呆症治疗率和死亡率:研究对象包括 891,418 名在全国糖尿病服务计划(National Diabetes Services Scheme)中登记的 2 型糖尿病患者,以及随机抽样的人群对比组(n = 1,131,369 人)。研究结果包括痴呆死亡(全因痴呆、阿尔茨海默病(AD)或血管性痴呆)和首次处方胆碱酯酶抑制剂或美金刚:在全因痴呆死亡或痴呆药物处方的综合结果中,糖尿病组的痴呆风险过高,但随糖尿病确诊年龄和持续时间的变化而变化。70岁时,糖尿病病程为10年和5年的患者的痴呆死亡/药物处方率分别高出1.3倍(95 % CI 1.2,1.3)和1.1倍(95 % CI 1.1,1.2)。个别结果显示,糖尿病与血管性痴呆死亡发生率较高有关,而只有糖尿病病程超过 10 年的患者才会出现注意力缺失症死亡风险增加的情况。此外,糖尿病患者服用痴呆症药物的比例较低:结论:在糖尿病病程超过10年的情况下,AD死亡的发生率较高,而AD治疗的发生率较低,这表明2型糖尿病患者对这种痴呆表型的认识不足。
Impact of type 2 diabetes and its duration on incidence rates of dementia death and medication prescription in the Australian population during 2003–2016
Aims
To quantify rates of dementia treatment and death among Australians with type 2 diabetes relative to those without diabetes using linked national registries of Australia.
Methods
The study included 891,418 people with type 2 diabetes registered on the National Diabetes Services Scheme and a randomly sampled, population-based comparison group (n = 1,131,369). Outcomes included dementia death (all-cause dementia, Alzheimer’s disease (AD) or vascular dementia), and first prescription of cholinesterase inhibitors or memantine.
Results
Excess dementia risk was observed in the diabetes group for the composite outcome of all-cause dementia death or dementia medication prescription but varied with age at diabetes diagnosis and its duration. At age 70, the rate of dementia death/medication prescription was ∼1.3 (95% CI 1.2, 1.3) and 1.1 (95% CI 1.1, 1.2) times higher in people with ten and five years of diabetes duration, respectively. Individual outcomes showed that diabetes was associated with a higher incidence of vascular dementia death, whereas an increased risk of AD death was only observed beyond ∼10 years of diabetes duration. Further, the incidence of dementia medication prescription was lower among people with diabetes.
Conclusions
A higher incidence of AD death in the setting of 10+ years of diabetes duration coupled with a lower incidence of AD treatment suggests an under-recognition of this dementia phenotype among people with type 2 diabetes.
期刊介绍:
Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.